By clicking below you acknowledge that you are navigating away from temaetfs.com and will be connected to temafunds. Tema Global Limited manages both domains. Please take note of Tema's privacy policy, terms of use, and disclosures that may vary between sites.
Start investing now
.svg){kind=small}
Start investing now
Invest directly by choosing one of the brokers below
Start investing now
Invest directly by choosing one of the brokers below
Start investing now
Invest directly by choosing one of the brokers below
Start investing now
Invest directly by choosing one of the brokers below
Start investing now
Invest directly by choosing one of the brokers below
Start investing now
Invest directly by choosing one of the brokers below
Your are leaving temaetfs.com
Which fund are you interested in?
Life Sciences
HRTS 
GLP-1, Obesity & Cardiometabolic ETF
CANC
Oncology ETF
MNTL
Neuroscience and Mental Health ETF
Strategic Equity
TOLL
Monopolies and Oligopolies ETF
RSHO
American Reshoring ETF
VOLT(coming soon)
Tema Electrification ETF
LUX
Luxury ETF
.svg){kind=small}
.svg){kind=icon}
Back
Why MNTL ETF?
Unmet medical need
1 billion people worldwide suffer from CNS diseases. Many illnesses have limited disease modifying treatments and are a huge economic burden on healthcare systems.
Source: WHO
Innovation
An innovation wave is rising with the watershed launch of the first medicines for Alzheimer’s to breakthroughs in gene editing, non-opioid pain, and targeted treatments for depression.
Research expertise
The fund conducts deep and comprehensive research, in an effort to identify those companies that deliver breakthrough solutions at attractive valuations.
Growing Market
The outsized economic burden of these diseases means a large and fast-growing addressable market with high payer acceptance according to Tema’s research.
Uncorrelated
Performance of many companies relies on clinical or commercial success, which is an uncorrelated source of return.
Fund Overview
Fund Details
As of November 19, 2024
Primary Exchange
Nasdaq
Ticker
MNTL
AuM (USD)
$10,874,792
# of Holdings
47
Fund Inception Date
01/22/24
Gross Expense Ratio
0.99%
Net Expense Ratio*
0.75%
Implied Liquidity (# of shares)
ETF Implied liquidity is a representation of how many shares can potentially be traded daily in an ETF as portrayed by the creation unit. This is defined as the smallest value of the IDTS (Implied Daily Tradable Shares) for each holding in the creation unit.
1,830,508
Implied Liquidity (USD)
ETF Implied liquidity is a representation of how many shares can potentially be traded daily in an ETF as portrayed by the creation unit. This is defined as the smallest value of the IDTS (Implied Daily Tradable Shares) for each holding in the creation unit.
$45M
Shares Outstanding
440,000
Investment Advisor
Tema Global Limited
Sub-Investment Advisor
NEOS Investments, LLC
*Contractual expense cap for net expense ratio of 0.75% is in effect through 06/28/2027.
Fund Summary
The actively managed Tema Neuroscience and Mental Health ETF seeks to provide long-term growth of capital by investing in companies tackling diseases of the central nervous system and mental health. We have reached a watershed moment in innovation with the approval of the first disease modifying agent in Alzheimer’s with significant innovation following in neuropsychology and genetic neurological disorders. The complex combination of scientific, regulatory and financing risks requires investment and scientific expertise to navigate this secular theme.
Portfolio Manager
Investment Partner
David K. Song, MD, PhD, CFA
David Song, Investment Partner, has led biotechnology and healthcare investment teams throughout his extensive 25-year career at Rockefeller Capital Management, Millennium and Balyasny. He studied Economics and Biochemistry at Yale, is a medical doctor and has a PhD in Applied Economics from Wharton.
How does the Tema MNTL ETF fit in a portfolio?
Investment Style Box
Source: Tema. The investment style Box reveal’s a fund’s investment strategy by showing its investment style and market capitalization based on the fund’s portfolio holdings.
Potential Portfolio
Equity Allocation
3-5%
Equity Satellite
MNTL ETF
Equity core
Where could a position be funded from?
- Could be a more targeted alternative to existing healthcare or biopharma exposure in a portfolio.
- Provides a balanced exposure across key technologies and company risk profiles.
- Could replace a satellite position or a growth-oriented alpha driver.
FAQ
What is a Neuroscience and Mental Health ETF?
How many holdings are in the Tema's Neuroscience and Mental Health ETF?
What are the top companies included in Tema's Neuroscience and Mental Health ETF?
Why invest in a Mental Health ETF?
What types of companies are included in a Neuroscience and Mental Health ETF?
Why should I consider investing in a Mental Health ETF over other healthcare ETFs?
How do biotech ETFs differ from neuroscience and mental health ETFs?
Are there any risks associated with investing in a Mental Health ETF?
What factors should I consider before investing in a Mental Health ETF?
How are the companies within a Neuroscience and Mental Health ETF selected?
Is there a minimum investment required for a Neuroscience and Mental Health ETF?
How often are the holdings of a Neuroscience and Mental Health ETF updated?
What is the future outlook for Mental Health ETFs?
How can a Neuroscience and Mental Health ETF benefit my investment portfolio?
How to buy
*Neither Tema Global Limited nor undefined ETF are affiliated with these financial services firms. Their listing should not be viewed as a recommendation or endorsement.